Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma, and Collegium Pharma

Monday, October 30, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 30, 2017 /PRNewswire/ --

If you want a Stock Review on ADMS, NEOS, ZYNE, or COLL then come over

to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market today, DailyStockTracker.com observes the performance of Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Neos Therapeutics Inc. (NASDAQ: NEOS), Zynerba
Pharmaceuticals Inc. (NASDAQ: ZYNE), and Collegium Pharmaceutical Inc. (NASDAQ: COLL). Companies in the Generic Pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse. Register now and get full and free access to these DailyStockTracker.com research reports at:

http://dailystocktracker.com/register/

Adamas Pharmaceuticals 

Emeryville, California headquartered Adamas Pharmaceuticals Inc.'s shares recorded a trading volume of 554,692 shares last Friday. The stock finished the trading session 4.56% higher at $19.51. The Company's shares have gained 12.45% over the previous three months and 15.44% since the start of this year. The stock is trading above its 200-day moving average by 10.98%. Furthermore, shares of Adamas Pharma, which discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders, have a Relative Strength Index (RSI) of 46.62.

On October 26th, 2017, Adamas Pharma announced that it will report Q3 2017 financial results on November 02nd, 2017, after market close. Subsequently, the management team will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a corporate update. The webcast can be accessed live under the investor section of the Company's website. Access our complete research report on ADMS for free at:

http://dailystocktracker.com/registration/?symbol=ADMS

Neos Therapeutics 

On Friday, Grand Prairie, Texas headquartered Neos Therapeutics Inc.'s stock ended the session flat at $10.05. A total volume of 1.48 million shares was traded, which was above their three months average volume of 721,720 shares. The Company's shares have gained 15.52% in the last one month, 55.81% over the previous three months, and 71.79% on an YTD basis. The stock is trading 20.11% above its 50-day moving average and 38.04% above its 200-day moving average. Moreover, shares of Neos Therapeutics, which engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies, have an RSI of 67.61.

On October 26th, 2017, Neos Therapeutics ("NEOS") confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. ("PDLI") to acquire all of the outstanding shares of NEOS for $10.25 per share in cash. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the NEOS Board of Directors will carefully review and consider the PDLI proposal to determine the course of action that it believes is in the best interest of the Company and its shareholders. The complimentary research report on NEOS can be downloaded at:

http://dailystocktracker.com/registration/?symbol=NEOS

Zynerba Pharmaceuticals 

Devon, Pennsylvania headquartered Zynerba Pharmaceuticals Inc.'s stock ended the day 3.16% higher at $9.80 with a total trading volume of 297,751 shares. The Company's shares have gained 3.81% in the last month. The stock is trading 27.98% above its 50-day moving average. Additionally, shares of Zynerba Pharma, which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery, have an RSI of 59.97.

On October 02nd, 2017, research firm Cantor Fitzgerald upgraded the Company's stock rating from 'Neutral' to 'Overweight' while revising its previous target price from $4 a share to $17 a share. Register for free on DailyStockTracker.com and get access to the latest report on ZYNE at:

http://dailystocktracker.com/registration/?symbol=ZYNE

Collegium Pharmaceutical 

Shares in Canton, Massachusetts headquartered Collegium Pharmaceutical Inc. recorded a trading volume of 740,584 shares, which was above their three months average volume of 464,860 shares. The stock ended Friday's session 2.74% lower at $9.94. The Company's shares are trading below its 50-day moving average by 5.80%. Furthermore, shares of Collegium Pharma, which develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases, have an RSI of 36.22. Download your free research report on COLL at:

http://dailystocktracker.com/registration/?symbol=COLL

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store